Cargando…

Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q

The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.61...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilhelm, Alexander, Toptan, Tuna, Pallas, Christiane, Wolf, Timo, Goetsch, Udo, Gottschalk, Rene, Vehreschild, Maria J. G. T., Ciesek, Sandra, Widera, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473269/ https://www.ncbi.nlm.nih.gov/pubmed/34578275 http://dx.doi.org/10.3390/v13091693

Ejemplares similares

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion
por: Ferreira, Isabella A T M, et al.
Publicado: (2021)

Comparison of the Ct-values for genomic and subgenomic SARS-CoV-2 RNA reveals limited predictive value for the presence of replication competent virus
por: Roesmann, Fabian, et al.
Publicado: (2023)

The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera
por: Li, Gen, et al.
Publicado: (2021)

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
por: Wilhelm, Alexander, et al.
Publicado: (2022)

SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
por: Cherian, Sarah, et al.
Publicado: (2021)

Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics
por: Veleanu, Andrei, et al.
Publicado: (2022)

Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7
por: Widera, Marek, et al.
Publicado: (2021)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
por: Liu, Chang, et al.
Publicado: (2021)

Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach
por: Seadawy, Mohamed G., et al.
Publicado: (2022)

The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro
por: Kohmer, Niko, et al.
Publicado: (2021)

Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617
por: Fan, Lin-qian, et al.
Publicado: (2021)

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
por: Hu, Jie, et al.
Publicado: (2021)

Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication
por: Widera, Marek, et al.
Publicado: (2021)

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
por: Edara, Venkata-Viswanadh, et al.
Publicado: (2021)

Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach
por: Ranjan, Prashant, et al.
Publicado: (2022)

Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern
por: Pondé, R.A.A.
Publicado: (2022)

The surgions mate, 1617
Publicado: (1979)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2021)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2022)

Variant-specific RT-qPCR for rapid screening of B.1.617 mutations in SARS-CoV-2
por: Jallul, Mwada, et al.
Publicado: (2022)

SARS-CoV-2 screening strategies for returning international travellers: Evaluation of a rapid antigen test approach
por: Layer, Emily, et al.
Publicado: (2022)

Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination
por: Grikscheit, Katharina, et al.
Publicado: (2022)

Impact of E484Q and L452R Mutations on Structure and Binding Behavior of SARS-CoV-2 B.1.617.1 Using Deep Learning AlphaFold2, Molecular Docking and Dynamics Simulation
por: Jiao, Yanqi, et al.
Publicado: (2023)

Insights into the structure and dynamics of SARS-CoV-2 spike glycoprotein double mutant L452R-E484Q
por: Ahamad, Shahzaib, et al.
Publicado: (2022)

SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?
por: Pascarella, Stefano, et al.
Publicado: (2021)

Characterization of mutations modulating enhanced transmissibility of SARS-CoV-2 B.1.617+ (Delta) variant using In Silico tools
por: Shahhosseini, Nariman
Publicado: (2022)

Optimized qRT-PCR Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs
por: Toptan, Tuna, et al.
Publicado: (2020)

Emerging Variants of B.1.617 Lineage Identified Among Returning Chinese Employees Working in India — Chongqing Municipality, China, April 2021
por: Ye, Sheng, et al.
Publicado: (2021)

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity
por: Zhang, Li, et al.
Publicado: (2022)

Access control for LEP (478)
por: Neet, D A G
Publicado: (1983)

Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian Variant) From Predicted Spike Protein Structure
por: Hajj-Hassan, Houssein, et al.
Publicado: (2021)

Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD—A Target for Vaccine Development
por: Gupta, Deepali, et al.
Publicado: (2022)

Access control for LEP (478-REV)
por: Neet, D A G
Publicado: (1984)

In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion
por: Augusto, Gilles, et al.
Publicado: (2021)

Chromosome 18p11.2 harbors susceptibility marker: D18S452, for bipolar affective disorder
por: Andrabi, Mutahar, et al.
Publicado: (2013)

Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy
por: Baj, Andreina, et al.
Publicado: (2021)

Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight
por: Khan, Mohd Imran, et al.
Publicado: (2021)

1617. Assessment of Bloodstream Infections in Patients with Intrapartum Fever
por: Kamel, Barbara, et al.
Publicado: (2023)

Piano quartets K. 478 & K. 493
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_4a8id87qv71hh9fro63t34edtu